Skip to main content

Table 5 Utilities applied to the model

From: Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

Health state Utility Source
Progression-free survival from first-line treatment 0.764 LYM-3002 [24]
Progressed from first-line treatment 0.693 LYM-3002 [24]
Progression-free survival from second-line treatment 0.764 LYM-3002 [24]
Progressed from second-line treatment 0.45 Doorduijn, 2005 [34]